Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical trial AI platform extracting structured insights from unstructured medical records; NLP for patient eligibility matching, pharmacovigilance, and real-world evidence generation.
Mendel is a clinical trial data management and AI platform that accelerates pharmaceutical and biotech drug development by extracting structured insights from unstructured medical records — physician notes, pathology reports, lab results, and clinical documentation — using natural language processing to identify patients eligible for trials, adverse events, and endpoint assessments. Founded in 2017 and headquartered in San Francisco, Mendel raised approximately $35 million and serves life sciences companies, hospital systems, and CROs (contract research organizations) running clinical trials.
US YC W20 AI interior design platform with style preference discovery and room visualization; generating personalized moodboards and shoppable décor matches competing with Houzz for AI-native home design discovery.
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal design aesthetic, visualize how spaces would look with different furniture and décor, and find matching products from online retailers. Users select style preferences (mid-century modern, bohemian, minimalist, coastal) and color palettes (navy, salmon, olive, beige) and receive AI-generated moodboards and room transformation visuals in seconds — with the platform linking out to purchasable products that match the visualized design. Founded in 2020 and enhanced with more sophisticated AI algorithms in 2024-2025, Oda Studio serves the design discovery and product-matching need that exists in the early stages of home decorating before interior designers are typically engaged.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.